Aarey Drugs & Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−0.4%+19.8%+533.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+218.6%−49.4%+191.2%
+1,309.1%−88.9%+236.3%
−1.4%−14.1%+847.1%
−57.5%+77.7%+868.4%
+24.8%−21.9%+4.7%
+8.6%+4.3%+13.1%
+5.0%+22.3%+120.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AAREYDRUGS₹110.84

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹315 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+533.3+19.8-0.4—
EBITDA Growth—+191.2-49.4+218.6—
EBIT Growth—+236.3-88.9+1,309.1—
Net Income Growth—+847.1-14.1-1.4—
EPS Growth—+868.4+77.7-57.5—
Total Assets Growth—+4.7-21.9+24.8—
Total Equity Growth—+13.1+4.3+8.6—
Cash from Operations Growth—+120.2+22.3+5.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.